Trials / Completed
CompletedNCT00327691
A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels
The Effect Of LDL-Cholesterol, Lowering Beyond Currently Recommended Minimum Targets On Coronary Heart Disesse (CHD) Recurrence In Patients With Pre-Existing CHD
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 8,600 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 35 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients with pre-existing CHD. Secondary objectives include the safety profile of this treatment strategy, its cost-effectiveness, effect on other atherosclerotic-related events and procedures, and total mortality.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atorvastatin |
Timeline
- Start date
- 1998-04-01
- Completion
- 2004-08-01
- First posted
- 2006-05-18
- Last updated
- 2007-05-03
Locations
314 sites across 14 countries: United States, Australia, Austria, Belgium, Canada, France, Germany, Ireland, Italy, Netherlands, South Africa, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00327691. Inclusion in this directory is not an endorsement.